Source: Medthority

Kite Pharma: Tecartus Data Reinforces Efficacy at ASH 2024

Longest follow-up data for Tecartus at ASH 2024 confirms durable efficacy and survival benefits

Read full article »
Kite Pharma's Competitors | Kite Pharma's News | Kite Pharma's Financials
Stay up-to-date with the latest news on Kite Pharma
Est. Annual Revenue
$25-100M
Est. Employees
1.0-5.0K
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on Kite Pharma